Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Everolimus for Resected Metastatic Pancreatic Neuroendocrine Tumors
NCT02031536Phase 2Terminated
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Apr 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Pancreatic neuroendocrine tumor (PanNET) comparing Arm A (everolimus) with Arm B (placebo) (2 arms). Primary endpoint: Disease Free Survival up to 5 years. Started Apr 2014; status: terminated.
02
Drugs
everolimus
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02031536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031536.